Nyxoah SA at Canaccord Genuity Growth Conference Transcript
Thank you for joining us at Canaccord's 43rd Annual Global Growth Conference. I'm Bill Plovanic, one of the Canaccord senior medical technology analysts. We're excited to host Nyxoah, and with us today from Nyxoah is Olivier Taelman, CEO, and Loïc Moreau, CFO. We're going to do a presentation, followed by a Q&A when we're -- after the presentation. And with that, I'll hand the podium over to Olivier.
Okay, thank you, and thank you for having us and inviting Nyxoah to the conference. The Nyxoah story is a story that is a story of neuromodulation in the field of obstructive sleep apnea. So I already can go to the first slide, and we like to call it Nyxoah's blueprint for success, or I'd like to refer to this as the trinity for success in medtech. In fact, there are three key pillars.
One is you need to have an existing and a large market. If we look at obstructive sleep apnea, I think it's obvious that the market is huge. We see, in the US alone, a $10 billion
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |